TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03741478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLANZapine 2.5 MG
Description: Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~1. Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~2. Cognitive arm - 5mg on Day 0, 10mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLANZapine 2.5 MG
Description: Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~1. Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~2. Cognitive arm - 5mg on Day 0, 10mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro 100 UNT/ML
Description: Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro 100 UNT/ML
Description: Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
Study: NCT03381833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LJPC-401
Description: subcutaneous injection, up to 20 mg per week from week 26 to 52

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LJPC-401
Description: subcutaneous injection, up to 20 mg per week from week 1 to 52
Study: NCT02688322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam
Description: 2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
Study: NCT02642588

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: energy gel
Description: energy gel: gelatinous edible containing carbohydrates typically used during endurance races
Study: NCT04465201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP with Smart Assist (Circulatory Support System)
Description: Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
Study: NCT00053898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg/day and placebo for 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20 mg/day and placebo for 5 years

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Adjuvant radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Adjuvant radiation therapy
Study: NCT05429775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: single dose of 2 mg oral suspension formulation administered orally under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: single dose of 2 mg oral suspension formulation administered orally under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: single dose of 2 mg oral suspension formulation administered orally under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: single dose of 2 mg oral suspension formulation administered orally under fasting conditions
Study: NCT03870958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GIC sealant (GC Fuji TRIAGE®)
Description: Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Children allocated to this group will receive the same dietary advices and brushing instructions.
Study: NCT02995369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DryShield
Description: DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DryShield
Description: DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DryShield
Description: DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DryShield
Description: DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
Study: NCT00004054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 135 mg/m\^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone releasing hormone [LHRH] agonist
Description: Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
Study: NCT02995369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cotton rolls
Description: Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cotton rolls
Description: Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
Study: NCT00004054

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
Study: NCT00004054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: To keep international normalized ratio (INR) \> 1.5 and \< 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
Study: NCT01138878

Intervention type: OTHER
Intervention: Questionnaire
Description: Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting

Intervention type: OTHER
Intervention: Questionnaire
Description: Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting

Intervention type: OTHER
Intervention: Questionnaire
Description: Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting

Intervention type: OTHER
Intervention: Questionnaire
Description: Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting

Intervention type: OTHER
Intervention: Focus Group Discussion
Description: FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
Study: NCT02521155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safeguard Your Smile an oral health literacy intervention
Description: Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month.
Study: NCT01634932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular iron
Description: Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron biofortified millet
Description: Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-harvest iron-fortifed millet
Description: Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
Study: NCT01666223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid
Description: 1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline
Description: 100 ml saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg
Description: Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
Study: NCT00802360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropin
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropin
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestrone vaginal insert
Description: 100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestrone vaginal insert
Description: 100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follitropin beta
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follitropin beta
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in oil
Description: 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone in oil
Description: 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
Study: NCT01418495

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01911858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Askina Calgitrol Paste
Study: NCT01186393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index
Description: Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Glycemic Index
Description: Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
Study: NCT03425708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg Febuxostat
Description: Participants take 20mg febuxostat pill once a day for at least six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg Febuxostat
Description: Participants take 40mg febuxostat pill once a day for at least six months.
Study: NCT01461681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symptom Management Service for Heart failure
Description: The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
Study: NCT00271388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous current to the vestibular nerve
Description: Delivery of randomly oscillating low level current
Study: NCT01413958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
Study: NCT01614964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ-13 Treatment
Description: Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem Treatment
Description: Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
Study: NCT03030287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-305B83
Description: intravenous (in the vein) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: administered intravenously
Study: NCT03689192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARG1-18,19,20
Description: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
Study: NCT01332448

Intervention type: DRUG
Intervention: Orlistat 120
Description: Orlistat 120mg tid

Intervention type: DRUG
Intervention: Orlistat 120
Description: Orlistat 120mg tid

Intervention type: DRUG
Intervention: Orlistat 60
Description: Orlistat 60mg tid

Intervention type: DRUG
Intervention: Orlistat 60
Description: Orlistat 60mg tid
Study: NCT00733525

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Therapy focusing on skills needed to alter eating patterns

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Therapy focusing on skills needed to alter eating patterns

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help
Description: Manual designed to impart teachings of cognitive behavioral therapy
Study: NCT03546205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.